George Mason University Antonin Scalia Law School

Author: C-IP2

C-IP2 Winter 2024 Progress Report (September-November 2024)

Warmest wishes for this holiday seasons and a Happy New Year from the C-IP2 team!
Headshot of Joshua KreshGreetings from C-IP2 Interim Executive Director Joshua A. Kresh

Reflecting on this vibrant winter season at the Center for Intellectual Property x Innovation Policy, I am filled with gratitude and excitement. As you can read in the report linked below, which covers this past September through November, we have been active and productive, hosting public and private events and supporting academic writing, including an amicus brief to the 9th Circuit submitted by Professor Sandra Aistars and Matthew Hersh, policy briefs on pending legislation (particularly a brief on RESTORE by Dr. Read more

Panel on “SEP Current & Proposed Regulations” at C-IP2’s 2024 Annual Fall Conference

By Keith Mallinson

It was my pleasure to participate in a panel session on “SEP Current & Proposed Regulations” last month at the George Mason University Antonin Scalia Law School Center for Intellectual Property x Innovation Policy (C-IP2) Annual Fall Conference entitled “The Importance of Exclusive Rights.” Read more

Panelists at George Mason’s IP conference debate litigation funding

By Kristen Osenga

I recently had the pleasure of participating in a panel on third-party litigation funding (TPLF), which was part of the Annual Fall Conference at George Mason University’s Center for Intellectual Property x Innovation Policy.

The panel included experts from both industry and academia, highlighted the growing debate around TPLF, and crystallized why this financing tool is so crucial for America’s innovators and inventors. Read more

What the FTC Gets Wrong About the FDA’s Orange Book

By Emily Michiko Morris & Douglas Park

The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role is misguided. The FTC has criticized the listing of drug product device patents in the FDA’s “Orange Book,” a listing of patents related to various FDA-approved drug products. Read more

Copyright and Tattoos: New Amicus Brief in Sedlik v. Von Drachenberg; Oct. 29 Virtual Clinic for Visual Artists

CIP2 congratulates the Arts & Entertainment Advocacy Clinic at Scalia Law, led by Professor Sandra Aistars, and Student Advocate Natalie Nachman, and supported by Counsel of Record Matt Hersh of Mestaz Law, for filing a powerful amicus brief on behalf of three Tattoo Artists in the 9th Circuit Court of Appeals this week in Sedlik v.

Read more

C-IP2 Fall 2024 Progress Report (June-August 2024)

Headshot of Joshua KreshGreetings from C-IP2 Interim Executive Director Joshua A. Kresh

As we transition into the fall season, I am delighted to share that we have had a productive summer and are looking forward to an eventful fall and winter. The past months have been marked by significant achievements and exciting developments, building upon the robust foundation we laid earlier this year. Read more

C-IP2 Summer 2024 Progress Report (March-May 2024)

Headshot of Joshua KreshGreetings from C-IP2 Interim Executive Director Joshua A. Kresh

I am pleased to report that we have had a productive spring and are working on several items for this summer and fall. Since our last report, we published several policy briefs on pending legislation, held our launch event for our 5G book, welcomed our new Edison Fellows for their first meeting (and saw several publications from earlier Fellows), and ran the 2024 WIPO-U.S. Read more